Vaccination is the most effective method for preventing infection, which is especially important in immunocompromised children treated with immunomodulatory therapy. Children with immune-mediated diseases are commonly treated with these drugs; therefore, infections present a major danger to their health. Despite that fact, the vaccine coverage remains low in these children, professional’s approach to vaccinations could probably be improved and parents accordingly addressed about the importance of vaccination in their children.
In 2011, EULAR published the first recommendations for vaccinations in children with rheumatic diseases. Update of recommendations is pending. Vaccinations with non-live vaccines are generally advised regardless of immunomodulatory therapy. Vaccination with live attenuated vaccines is not recommended in patients who are treated with high doses of GCS or other immunomodulatory drugs, including biologics. However, in cases of high-risk of infection, vaccination can be considered on a case-to-case basis, weighing the risk of infection against the risk of vaccination. The level of evidence for this approach is low. However, recently new data on safety of MMR booster in a large group of patients treated with immunomodulatory drugs, including biologics, emerge. But we still need more firm evidence on safety and immunogenicity of live attenuated vaccines in children treated with immunosuppressive drugs.
Other aspects of vaccination in children with immune-mediated diseases, such as ethics of vaccination, the diversity of national vaccination programmes and adverse events following vaccinations need to be addressed too.
The goal of this Research Topic is to address different aspects of vaccinations in children with immune mediated diseases:
- Vaccine coverage in children with immune-mediated diseases
- Approach of professionals (primary care physicians, infectious disease specialists, rheumatologist, nurses) towards vaccination
- Approach of parents toward vaccination
- Ethics of vaccination
- Risk of infections
- Vaccination with non-live vaccines- safety and immunogenicity
- Vaccination with live attenuated vaccines- safety and immunogenicity
- COVID-19 in children with immune mediated diseases
- Vaccination against COVID-19 in children with immune-mediated diseases
This collection will include all aspects of vaccination in children with immune-mediated diseases, from risk of infections, vaccine coverage, approach to vaccinations in different countries, ethics of vaccination, safety and immunogenicity of non-live and live attenuated vaccines and COVID 19 risk and vaccination.
We would encourage authors to send original studies, important preliminary results of the studies that might change approach to vaccinations, review articles and meta- analysis
Vaccination is the most effective method for preventing infection, which is especially important in immunocompromised children treated with immunomodulatory therapy. Children with immune-mediated diseases are commonly treated with these drugs; therefore, infections present a major danger to their health. Despite that fact, the vaccine coverage remains low in these children, professional’s approach to vaccinations could probably be improved and parents accordingly addressed about the importance of vaccination in their children.
In 2011, EULAR published the first recommendations for vaccinations in children with rheumatic diseases. Update of recommendations is pending. Vaccinations with non-live vaccines are generally advised regardless of immunomodulatory therapy. Vaccination with live attenuated vaccines is not recommended in patients who are treated with high doses of GCS or other immunomodulatory drugs, including biologics. However, in cases of high-risk of infection, vaccination can be considered on a case-to-case basis, weighing the risk of infection against the risk of vaccination. The level of evidence for this approach is low. However, recently new data on safety of MMR booster in a large group of patients treated with immunomodulatory drugs, including biologics, emerge. But we still need more firm evidence on safety and immunogenicity of live attenuated vaccines in children treated with immunosuppressive drugs.
Other aspects of vaccination in children with immune-mediated diseases, such as ethics of vaccination, the diversity of national vaccination programmes and adverse events following vaccinations need to be addressed too.
The goal of this Research Topic is to address different aspects of vaccinations in children with immune mediated diseases:
- Vaccine coverage in children with immune-mediated diseases
- Approach of professionals (primary care physicians, infectious disease specialists, rheumatologist, nurses) towards vaccination
- Approach of parents toward vaccination
- Ethics of vaccination
- Risk of infections
- Vaccination with non-live vaccines- safety and immunogenicity
- Vaccination with live attenuated vaccines- safety and immunogenicity
- COVID-19 in children with immune mediated diseases
- Vaccination against COVID-19 in children with immune-mediated diseases
This collection will include all aspects of vaccination in children with immune-mediated diseases, from risk of infections, vaccine coverage, approach to vaccinations in different countries, ethics of vaccination, safety and immunogenicity of non-live and live attenuated vaccines and COVID 19 risk and vaccination.
We would encourage authors to send original studies, important preliminary results of the studies that might change approach to vaccinations, review articles and meta- analysis